Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.43 |
| ▸ | NOS3 | P29474 | 8/20 | 0.43 |
| ▸ | TKT | P29401 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | HEXA | P06865 | 3/20 | 0.37 |
| ▸ | HEXB | P07686 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28084073 | 0.82 | NOS2 (0.47) | NOS2NOS3NOS1KDM4EPOLB | |
| SCHEMBL10399548 | 0.81 | NOS3 (0.39) | NOS2NOS3TKTNOS1HEXA | |
| SCHEMBL18611206 | 0.79 | TDP1 (0.36) | NOS2NOS3TKTPARP1 | |
| SCHEMBL10730430 | 0.78 | NOS3 (0.46) | NOS2NOS3TKTNOS1HEXA | |
| SCHEMBL10162551 | 0.77 | NOS3 (0.36) | NOS2NOS3TKTHEXAHEXB | |
| SCHEMBL5532296 | 0.77 | PARP1 (0.39) | NOS2NOS3TKTPARP1KDM4E | |
| SCHEMBL20110642 | 0.76 | ALDH1A1 (0.35) | NOS2NOS3TKTNOS1PARP1 | |
| SCHEMBL11814271 | 0.76 | MEN1 (0.35) | NOS2NOS3TKTNOS1HEXA | |
| SCHEMBL27965565 | 0.76 | NOS3 (0.35) | NOS2NOS3NOS1KDM4EPOLB | |
| SCHEMBL21604163 | 0.74 | NOS3 (0.42) | NOS2NOS3TKTNOS1HEXA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-8193372-B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| WO-1991017979-A1 | PROCESS FOR THE PREPARATION OF 2-N-ACYLAMINOPYRIDINES AND 2-AMINOPYRIDINES FROM 5-OXOALKANENITRILE OXIMES | DSM N.V. (NL) | 1991-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | POLR2H, POLR2E, EIF2AK2 | NOS2 2892/4885NOS3 3431/4885TKT 1804/4885 |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | NOS2 3595/4885NOS3 3633/4885TKT 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.